GenVec Inc. has initiated a Phase II clinical study to evaluate the anti-cancer activity of TNFerade in patients with metastatic melanoma.

The study will assess tumor response after four weeks of intratumoral injections of TNFerade plus simultaneous radiation therapy in 29 patients with stage III or IV metastatic melanoma who are ineligible for surgery or unlikely to benefit from other treatment options.